CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

NCT04269213 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia

Interventions

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]